Menu
Search
|

Menu

Close
X

Neogenomics Inc NEO.OQ (NASDAQ Stock Exchange Capital Market)

16.50 USD
-0.13 (-0.78%)
As of 2:29 AM IST
chart
Previous Close 16.63
Open 16.65
Volume 289,300
3m Avg Volume 194,693
Today’s High 16.78
Today’s Low 16.33
52 Week High 19.02
52 Week Low 7.08
Shares Outstanding (mil) 93.02
Market Capitalization (mil) 1,546.87
Forward P/E 324.55
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.38 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
200
FY17
247
FY16
244
FY15
100
EPS (USD)
FY18
0.060
FY17
-0.171
FY16
-0.391
FY15
-0.044
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
324.55
28.86
Price to Sales (TTM)
vs sector
5.77
23.49
Price to Book (MRQ)
vs sector
5.09
3.93
Price to Cash Flow (TTM)
vs sector
60.37
20.30
Total Debt to Equity (MRQ)
vs sector
36.34
15.17
LT Debt to Equity (MRQ)
vs sector
31.77
11.36
Return on Investment (TTM)
vs sector
1.19
12.65
Return on Equity (TTM)
vs sector
2.11
14.38

EXECUTIVE LEADERSHIP

Douglas VanOort
Chairman of the Board, Chief Executive Officer, Since 2009
Salary: $616,346.00
Bonus: --
George Cardoza
President - Pharma Services Division, Since 2018
Salary: $352,692.00
Bonus: --
Sharon Virag
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Robert Shovlin
President - Clinical Services Division, Since 2016
Salary: $350,000.00
Bonus: --
Steven Jones
Executive Vice President, Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Healthcare Facilities & Services
Address:

12701 Commonwealth Dr Ste 9
FORT MYERS   FL   33913-8626

Phone: +1941.9231949

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

SPONSORED STORIES